Display options
Cite
Mackay FJ. Post-marketing studies: the work of the Drug Safety Research Unit. Drug Saf. 1998;19(5):343-53doi: 10.2165/00002018-199819050-00002.
Mackay, F. J. (1998). Post-marketing studies: the work of the Drug Safety Research Unit. Drug safety, 19(5), 343-53. https://doi.org/10.2165/00002018-199819050-00002
Mackay, F J. "Post-marketing studies: the work of the Drug Safety Research Unit." Drug safety vol. 19,5 (1998): 343-53. doi: https://doi.org/10.2165/00002018-199819050-00002
Mackay FJ. Post-marketing studies: the work of the Drug Safety Research Unit. Drug Saf. 1998 Nov;19(5):343-53. doi: 10.2165/00002018-199819050-00002. PMID: 9825948.
Copy Download .nbib Format: NLM
Share it on
Full text links
Springer

Drug Saf. 1998 Nov;19(5):343-53. doi: 10.2165/00002018-199819050-00002.

Post-marketing studies: the work of the Drug Safety Research Unit.

Drug safety

F J Mackay

Affiliations

  1. Drug Safety Research Unit, Southampton, England. [email protected]

PMID: 9825948 DOI: 10.2165/00002018-199819050-00002

Abstract

The Drug Safety Research Unit (DSRU) is the centre for prescription-event monitoring (PEM) in England. PEM studies are noninterventional observational cohort studies which monitor the safety of newly marketed drugs. The need for post-marketing surveillance is well recognised in the UK and general practice is an ideal source of data. PEM studies are general practitioner (community)-based and exposure is based on dispensed prescription data in England. To date, 65 PEM studies have been completed with a mean cohort size of 10 979 patients and the DSRU database has clinical information on over 700000 patients prescribed new drugs. Unlike spontaneous reporting schemes, PEM produces incidence rates for events reported during treatment. Comparative studies can be conducted for drugs in the same class. The DSRU aggregates outcome data for pregnancies exposed to new drugs. Data for children and the elderly can also be specifically examined. PEM data have a number of advantages over data from computerised general practice databases in the UK. PEM is the only technique within the UK capable of monitoring newly marketed drugs in such a comprehensive and systematic way.

Cited by

References

  1. Drug Saf. 1997 Jun;16(6):355-65 - PubMed
  2. BMJ. 1998 Jan 31;316(7128):343-5 - PubMed
  3. Br J Clin Pharmacol. 1993 Jun;35(6):599-602 - PubMed
  4. Br Med J (Clin Res Ed). 1988 Feb 6;296(6619):399-400 - PubMed
  5. BMJ. 1996 Sep 21;313(7059):732-3; discussion 733-4 - PubMed
  6. J Clin Epidemiol. 1990;43(5):509-22 - PubMed
  7. Epilepsia. 1997 Aug;38(8):881-6 - PubMed
  8. Pharmacoepidemiol Drug Saf. 1997 Jul;6(4):235-46 - PubMed
  9. Br J Obstet Gynaecol. 1998 Aug;105(8):882-9 - PubMed
  10. BMJ. 1992 Jun 6;304(6840):1470-2 - PubMed
  11. Drugs. 1993 Oct;46(4):585-93 - PubMed
  12. BMJ. 1991 Mar 30;302(6779):763-5 - PubMed
  13. Br J Gen Pract. 1998 Apr;48(429):1161-2 - PubMed
  14. BMJ. 1991 Mar 30;302(6779):766-8 - PubMed
  15. BMJ. 1993 Oct 2;307(6908):846-8 - PubMed
  16. BMJ. 1996 Sep 21;313(7059):756 - PubMed
  17. Br J Clin Pharmacol. 1995 Mar;39(3):223-6 - PubMed
  18. Br J Gen Pract. 1995 Oct;45(399):537-41 - PubMed
  19. Br Med J (Clin Res Ed). 1988 May 7;296(6632):1319 - PubMed
  20. Pharmacoepidemiol Drug Saf. 1997 Jul;6(4):283-9 - PubMed
  21. Lancet. 1998 Mar 14;351(9105):802 - PubMed
  22. Pharmacoepidemiol Drug Saf. 1997 Oct;6 Suppl 3:S5-11 - PubMed
  23. BMJ. 1991 Mar 30;302(6779):741-2 - PubMed
  24. Thorax. 1998 Jul;53(7):558-62 - PubMed
  25. Pharmacoepidemiol Drug Saf. 1996 Nov;5(6):363-75 - PubMed

Substances

MeSH terms

Publication Types

LinkOut - more resources